Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize.
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious.
/PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious.